Elin Dahl trained as a hospital internist before adding a specialty in clinical pharmacology, and the two halves show in how she reads the Myrto Med postbag. She is used to the patient who arrives on six medicines and a vague worry, and to the pharmacology question underneath it — what a drug is doing to a receptor, an enzyme or a channel, and whether that explains the symptom in front of her. She answers in that register: exact about mechanism, honest about uncertainty, and unwilling to pretend a webpage can examine anyone.
The five medicines on this site sit at the intersection she works in every week. Three are phosphodiesterase-5 inhibitors that preserve a vascular signal arousal has already begun; one is a fluoroquinolone antibiotic with real reach and real teeth; one is a calcium-channel modulator that quiets over-firing nerves. She can explain each in a sentence a patient will remember, then mark clearly where the trial evidence is thin and where the marketing has run ahead of it.
A handful of rules she states without softening. The PDE5 tablets — tadalafil, sildenafil, vardenafil — must never be combined with nitrates in any form, because the pair can drop blood pressure to a dangerous level. Ciprofloxacin carries a fluoroquinolone boxed warning for tendon rupture, nerve damage and central-nervous-system effects, and is not a casual first choice for a minor infection. Gabapentin is stopped by tapering, never abruptly, and it multiplies the sedation of opioids and alcohol. She repeats these because they are the errors most likely to cause harm.
She is sceptical of the story each of these drugs is sold with. None of the ED tablets manufactures desire. An antibiotic as powerful as ciprofloxacin is a liability when used for something a narrower drug would clear. Gabapentin helps some nerve-pain and seizure patients a great deal and does very little for ordinary back pain, however often it is reached for. She would rather a reader leave correctly informed and slightly deflated than briefly reassured and wrong.
Everything she writes points at something a reader can open and check — the current FDA label, the EMA assessment, MedlinePlus, a named trial — because an answer nobody can verify is worth little to her. And every reply carries the same caveat in spirit: this is general teaching, not a plan built for you. When the honest answer turns on your kidneys, your other medicines, your tendons or your seizure history, she says so, and sends you back to a clinician who can see the whole record.
Last Updated